Thursday, October 24, 2024 9:28:45 PM
An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html
The webcast https://lyell-company-update-2024.open-exchange.net/registration
Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
The webcast https://lyell-company-update-2024.open-exchange.net/registration
Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
Recent LYEL News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:07:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:06:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:05:53 PM
- Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/03/2026 08:23:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:26:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:24:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:50:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:12:21 PM
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results • GlobeNewswire Inc. • 03/12/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:05:17 PM
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 01:46:32 AM
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma • GlobeNewswire Inc. • 02/12/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:05:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:00:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 01:58:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:02:57 PM
- Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge • GlobeNewswire Inc. • 12/24/2025 11:00:00 AM
- Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 • PR Newswire (Canada) • 12/19/2025 12:44:00 PM
